Universal flu vaccine developer BiondVax mulling IPO: Globes

Israel's BiondVax Pharmaceuticals, whose universal flu vaccine candidate has so far undergone a successful Phase II trial and is set for another next year, is thinking about a Wall Street IPO, according to Israeli newspaper Globes. Sources tell the paper the company, which has no revenue and cash reserves of 14.1 million shekels ($3.5 million), is exploring a conventional offering or listing American Depository Receipts for trading. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.